AYSEL VEHAPOĞLU TÜRKMEN, Nilüfer GÖKNAR, Rümeysa TUNA, Fatma Betül ÇAKIR

Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin

VehapoğluA, GöknarN, TunaR, Çakır FB. Ceftriaxoneinduced hemolytic anemia in a child successfully managed with intravenous immunoglobulin. Turk J Pediatr 2016; 58: 216-219.Drug-induced hemolytic anemia is an immune-mediated phenomenon that leads to the destruction of red blood cells. Here, we present a case of lifethreatening ceftriaxone-induced hemolytic anemia (CIHA) in a previously healthy 3-year-old girl. We also reviewed the literature to summarize the clinical features and treatment of hemolytic anemia. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with high mortality. Our patient had a sudden loss of consciousness with macroscopic hematuria and her hemoglobin dropped from 10.2 to 2.2 g/dl over 4 hours, indicating that the patient had life-threatening hemolysis after an intravascular dose of ceftriaxone who had previously been treated with ceftriaxone in intramuscular form for six days. CIHA is associated with a positive direct antiglobulin test, revealing the presence of IgG in all cases and C3d in most cases. Our patient's direct antiglobulin test was positive for IgG (3+) and for C3d (4+). The case was managed successfully with supportive measures and intravenous immunoglobulin therapy. Ceftriaxone is used very frequently in children; an early diagnosis and proper treatment of hemolytic anemia are essential to improve the patient outcome. The pathophysiological mechanism is the same as for non-drug autoimmune hemolytic anemia. However, there is still no consensus treatment for CIHA. Intravenous immunoglobulin can be used in clinical emergencies, such as our case, or in refractory cases.

PDF

___

1. Chen F, Zhan Z. Severe drug-induced immune haemolytic anaemia due to ceftazidime. Blood Transfus 2014; 12: 435-437.

2. Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 2014; 30: 66-79.

3. Rocephin (ceftriaxone sodium) injection, powder, for solution [Genentech, Inc].

4. Arndt PA. Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology 2014; 30: 44-54.

5. Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology 2014; 30: 85-94.

6. Quillen K, Lane C, Hu E, Pelton S, Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J 2008; 27: 357-358.

7. Pierce A, Nester T. Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol 2011; 136: 7-12.

8. Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol 2015; 37: e63-e66.

9. Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with druginduced immune hemolytic anemia. Transfusion 2012; 52: 602-612.

10. Liu W, Yu D. Adverse drug reactions during ceftriaxone treatment can cause severe hemolysis. Pediatr Allergy Immunol 2014; 25: 101-102.

11. Zanetti RC, Biswas AK. Hemolytic anemia as a result of piperacillin/tazobactam administration: a case report and discussion of pathophysiology. Mil Med 2013; 178: 1045- 1047.

12. Chen X, Ghaffar H, Jen CC, et al. Antibody specific for the glycophorin A complex mediates intravenous immune globulin-resistant anemia in a murine model. Transfusion 2014; 54: 655-664.